Risk Factors for Acquisition of Imipenem-resistant Acinetobacter Baumannii: a Case-control Study

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2003 Dec 25

PMID 14693543

Citations 46

Authors

Sang-Oh Lee

Nam Joong Kim

Sang-Ho Choi

Tae Hyong Kim

Jin-Won Chung

Jun-Hee Woo

Jiso Ryu

Yang Soo Kim

Affiliations

Soon will be listed here.

Abstract

Risk factors for the nosocomial occurrence of imipenem-resistant Acinetobacter baumannii (IRAB) were determined. A case-control study design was used for a comparison of two groups of A. baumannii-positive patients with control patients. Nosocomial IRAB was isolated from the first group of A. baumannii-positive patients, and imipenem-susceptible A. baumannii (ISAB) was isolated from the second group. The control patients were randomly selected in a 4:1 ratio from the same medical or surgical services from which the A. baumannii-positive patients were receiving care when the isolation of IRAB occurred. Risk factors analyzed included demographic variables, comorbid conditions, variables related to hospitalization, and the antimicrobials used. IRAB was isolated from 104 patients, and ISAB was isolated from 387 patients between January and December 2000. The risk factors for IRAB were a previous intensive care unit (ICU) stay (odds ratio [OR], 21.54; 95% confidence interval [CI], 10.73 to 43.23) and prior exposure to imipenem (OR, 9.18; 95% CI, 3.99 to 21.13) or third-generation cephalosporins (OR, 2.11; 95% CI, 1.13 to 3.95). Risk factors for ISAB were a previous ICU stay (OR, 8.05; 95% CI, 5.67 to 11.44) and exposure to third-generation cephalosporins (OR, 2.07; 95% CI, 1.47 to 2.91). Our results suggest that the nosocomial occurrence of IRAB or ISAB is strongly related to an ICU stay, and IRAB occurrence may be favored by the selection pressure of imipenem.

Citing Articles

A machine-learning model for prediction of Acinetobacter baumannii hospital acquired infection.

Neuman I, Shvartser L, Teppler S, Friedman Y, Levine J, Kagan I PLoS One. 2024; 19(12):e0311576.

PMID: 39636870 PMC: 11620386. DOI: 10.1371/journal.pone.0311576.

Insights into the epidemiology, risk factors, and clinical outcomes of carbapenem-resistant infections in critically ill children.

Zhang Y, Xu G, Miao F, Huang W, Wang H, Wang X Front Public Health. 2023; 11:1282413.

PMID: 38098829 PMC: 10720883. DOI: 10.3389/fpubh.2023.1282413.

Epidemiologic Correlation and Drug Resistance Analysis of Pathogenic Bacteria in Different Open Limb Injury External Conditions.

Xie B, Guo R, Liang W, Yang X, Xu J, Wan L Orthop Surg. 2022; 14(8):1703-1714.

PMID: 35765776 PMC: 9363730. DOI: 10.1111/os.13203.

Prevalence of Carbapenem-Resistant Infection in a Northern Province in China: Clinical Characteristics, Drug Resistance, and Geographic Distribution.

Wang N, Zhan M, Liu J, Wang Y, Hou Y, Li C Infect Drug Resist. 2022; 15:569-579.

PMID: 35228807 PMC: 8881927. DOI: 10.2147/IDR.S347343.

: Its Clinical Significance in Human and Veterinary Medicine.

Nocera F, Attili A, De Martino L Pathogens. 2021; 10(2).

PMID: 33513701 PMC: 7911418. DOI: 10.3390/pathogens10020127.

References

Fierobe L, Lucet J, Decre D, Muller-Serieys C, Deleuze A, Joly-Guillou M . An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients. Infect Control Hosp Epidemiol. 2001; 22(1):35-40. DOI: 10.1086/501822. View

Paterson D . Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach. Clin Infect Dis. 2002; 34(12):1564-7. DOI: 10.1086/340532. View

Harris A, Samore M, Lipsitch M, Kaye K, Perencevich E, Carmeli Y . Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis. 2002; 34(12):1558-63. DOI: 10.1086/340533. View

Harris A, Karchmer T, Carmeli Y, Samore M . Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis. 2001; 32(7):1055-61. DOI: 10.1086/319600. View

Jarvis W, Brook J, Culver D, Potts A, Gay E, Shotts B . Epidemic bacteremia due to Acinetobacter baumannii in five intensive care units. Am J Epidemiol. 1990; 132(4):723-33. DOI: 10.1093/oxfordjournals.aje.a115714. View

Contant J, Kemeny E, Oxley C, Perry E, Garber G . Investigation of an outbreak of Acinetobacter calcoaceticus var. anitratus infections in an adult intensive care unit. Am J Infect Control. 1990; 18(4):288-91. DOI: 10.1016/0196-6553(90)90171-n. View

Deyo R, Cherkin D, Ciol M . Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45(6):613-9. DOI: 10.1016/0895-4356(92)90133-8. View

Struelens M, Carlier E, Maes N, Serruys E, Quint W, van Belkum A . Nosocomial colonization and infection with multiresistant Acinetobacter baumannii: outbreak delineation using DNA macrorestriction analysis and PCR-fingerprinting. J Hosp Infect. 1993; 25(1):15-32. DOI: 10.1016/0195-6701(93)90005-k. View

Tankovic J, Legrand P, De Gatines G, Chemineau V, Brun-Buisson C, Duval J . Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods. J Clin Microbiol. 1994; 32(11):2677-81. PMC: 264141. DOI: 10.1128/jcm.32.11.2677-2681.1994. View

10.

Lortholary O, Fagon J, Hoi A, Slama M, Pierre J, Giral P . Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin Infect Dis. 1995; 20(4):790-6. DOI: 10.1093/clinids/20.4.790. View

11.

Mulin B, Talon D, Viel J, Vincent C, Leprat R, Thouverez M . Risk factors for nosocomial colonization with multiresistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis. 1995; 14(7):569-76. DOI: 10.1007/BF01690727. View

12.

Bergogne-Berezin E, Towner K . Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996; 9(2):148-65. PMC: 172888. DOI: 10.1128/CMR.9.2.148. View

13.

Kaul R, Burt J, Cork L, Dedier H, Garcia M, Kennedy C . Investigation of a multiyear multiple critical care unit outbreak due to relatively drug-sensitive Acinetobacter baumannii: risk factors and attributable mortality. J Infect Dis. 1996; 174(6):1279-87. DOI: 10.1093/infdis/174.6.1279. View

14.

Koeleman J, Parlevliet G, Dijkshoorn L, Savelkoul P, Vandenbroucke-Grauls C . Nosocomial outbreak of multi-resistant Acinetobacter baumannii on a surgical ward: epidemiology and risk factors for acquisition. J Hosp Infect. 1997; 37(2):113-23. DOI: 10.1016/s0195-6701(97)90181-x. View

15.

Afzal-Shah M, Livermore D . Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother. 1998; 41(5):576-7. DOI: 10.1093/jac/41.5.576. View

16.

Villers D, Espaze E, Coste-Burel M, Giauffret F, Ninin E, Nicolas F . Nosocomial Acinetobacter baumannii infections: microbiological and clinical epidemiology. Ann Intern Med. 1998; 129(3):182-9. DOI: 10.7326/0003-4819-129-3-199808010-00003. View

17.

Brooks S, Walczak M, Rizwanullah H . Are we doing enough to contain Acinetobacter infections?. Infect Control Hosp Epidemiol. 2000; 21(5):304. DOI: 10.1086/503224. View

18.

Corbella X, Montero A, Pujol M, Dominguez M, Ayats J, Argerich M . Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol. 2000; 38(11):4086-95. PMC: 87546. DOI: 10.1128/JCM.38.11.4086-4095.2000. View